Fig. 9From: Tumor-penetrating nanoplatform with ultrasound “unlocking” for cascade synergistic therapy and visual feedback under hypoxiaPosttreatment biosafety. (a-f) Routine blood examination of MDA-MB-231 tumor-bearing mice 16 days after administration of various treatments (inset dotted lines: upper and lower limits of the normal range) (n = 5). g Biochemical analysis of the blood of MDA-MB-231 tumor-bearing mice 16 days after administration of various treatments, including: hepatic function (ALT, AST, ALP, ALB) or renal indicators (UREA, CREA)Back to article page